<DOC>
	<DOCNO>NCT00782353</DOCNO>
	<brief_summary>The purpose study investigate safety , tolerability , antiviral activity ANA598 patient genotype-1 chronic hepatitis C infection .</brief_summary>
	<brief_title>Safety , Tolerability , Antiviral Activity ANA598 Patients With Genotype-1 Chronic HCV Infection</brief_title>
	<detailed_description>The safety , tolerability antiviral activity ANA598 , administer orally twice daily 3 day , compare placebo treatment-naïve subject chronically infect HCV genotype 1 infection . Thirty ( 30 ) subject randomize one three cohort describe . The ten patient cohort randomize 8 active : 2 placebo . At least 5 subject genotype 1a 5 subject genotype 1b enrol within cohort .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Male female , age 18 65 year Documented chronic HCV infection , genotype 1a 1b Treatmentnaïve BMI = 18 35 kg/m2 Female patient pregnant breastfeed Previous treatment HCV infection HIV HBV positive Evidence cirrhosis previous liver biopsy previous image study History know cause liver disease ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>HCV</keyword>
</DOC>